Tight Regulation of Erk Activity Protects From Anthracycline-Induced Cardiotoxicity Authors: Benedetta Coppe, Nadia Mercader Published: 2025 ABSTRACT Corresponding Author In a study reported in this issue of JACC: CardioOncology, Moossavi et al1 identified Erk inhibition as a potential therapeutic target for anthracycline-induced cardiotoxicity (AIC) that is used in patients with leukemia, lymphoma, sarcoma, and breast cancer.2 The etiology of AIC involves the accumulation of anthracycline metabolites, which trigger pathogenic mechanisms such as topoisomerase IIβ inhibition, calcium homeostasis disruption, myofibril degradation, mitochondrial damage, reactive oxygen species generation, and pathologic cell death.3 Accelerated cardiac aging has also been identified in a mouse model of AIC.4 Several molecular pathways, including MAPK, mTOR, β-adrenergic receptor, Ca2+/calmodulin-dependent kinase II, and Erk signaling, have been found to be dysregulated in AIC, making them key effectors in its pathophysiology.5 In the clinic, angiotensin-converting enzyme inhibitors, beta-blockers, and angiotensin receptor neprilysin inhibitors are usually administered in case of AIC-associated heart failure. However, the only approved drug specific for AIC prevention and treatment is dexrazoxane.6 Thus, there is a need for the identification of additional therapeutic strategies. The zebrafish is a vertebrate model organism widely used in the field of cardiovascular drug research.7 It has been proved to be a valid model to assess the effect of cardiovascular drugs and determine unwanted side effects of chemical compounds on the cardiovascular system.8 In the zebrafish model of AIC, retinoic acid–based and autophagy-based therapies, as well as specific microRNA cocktails, showed benefits in the treatment of AIC in a time-dependent manner.9, 10, 11 Indeed, the identification of molecular markers consistently activated throughout the progression of AIC could offer new therapeutic targets with broader clinical benefits. Moossavi et al1 used the zebrafish as a model of AIC to conduct genetic and pharmacologic screenings, enabling rapid analysis of potential therapeutic targets for doxorubicin-induced cardiotoxicity. They recapitulated AIC in the adult zebrafish by intraperitoneal injection of 1 dose of doxorubicin (20 mg/kg). To confirm cardiotoxicity, they assessed DNA double-strand breaks, cellular senescence, the expression of cell-cycle arrest–associated and cardiac hypertrophy–associated genes, as well as cardiac function. First, they confirmed the beneficial effects of senolytic and antiaging drug administration in the doxorubicin-treated zebrafish, supporting the contribution of cardiac senescence to heart dysfunction in AIC. Second, to identify potential target genes involved in the pathophysiology of AIC, they assessed cardiac function recovery in mutants for genes related to cardiomyopathy following doxorubicin injection. They observed that heterozygous mutants of mek1 and erk1, key components of the MAPK pathway, displayed reduced senescence markers and restored cardiac function, suggesting their cardioprotective effect. Interestingly, and confirming the previously observed cardiotoxic effect of the MEK1/2 inhibitor trametinib,12 complete erk1 inhibition in homozygous mutants resulted in cardiotoxicity. They further demonstrated the dual role of Erk inhibition on cardiac protection vs cardiotoxicity by modulating the inhibition of Erk in wild-type fish using dose-dependent pharmacologic treatments of trametinib, pluripotin, and temuterkib. Overall, through this study, Moossavi et al1 confirm the role of cellular senescence as a pathologic13 cardiac mechanism activated in response to anthracycline treatment and delineate the dose-dependent cardioprotective role of Erk inhibition in AIC. The zebrafish single-injection AIC model has shown significant potential in tackling molecular pathways involved in AIC progression, but the zebrafish’s ability to regenerate the heart may influence the outcome of disease modeling and treatment assessment. The investigators identified increased cellular senescence as well as proliferation in response to doxorubicin treatment, suggesting the activation of injury-induced regeneration. Although cellular senescence is detrimental in the human heart, it plays a crucial role in cardiac regeneration in the zebrafish,13 limiting its translatability to mammals. Caution should be exercised when translating the protective effects observed following Erk inhibition in zebrafish, as the outcomes of tested drugs might influence or be influenced by the regenerative process. A second limitation of this model is the absence of sexual dimorphism in doxorubicin-treated animals, which has been previously described in mammals, with males showing higher susceptibility to doxorubicin-induced cardiac damage.14,15 Therefore, future validation of selected genes and candidate drugs should be ultimately conducted in a mouse model of chronic AIC, in which sex should be accounted for as a biological variable. Equally important will be the characterization of downstream effectors implicated in the dose-dependent Erk inhibition, as well as the determination of the optimal dose required to induce cardioprotection, avoiding toxicity. As shown by the investigators, different Erk inhibitors have distinct effects, with SC1 showing toxicity in the healthy population, while temuterkib is the safest alternative. Thus, when assessing different drugs, particular caution should be taken in treatment dose optimization and safety validation in homeostatic and pathologic conditions, not only in zebrafish but also in mammalian models. Finally, treatments combining anthracyclines with candidate cardioprotective drugs should be evaluated to identify the safest and most effective compounds that do not compromise the efficacy of chemotherapy. Funding Support and Author Disclosures Dr Coppe has received funding from the DBMR-Johanna Durmüller Award. Dr Mercader has received funding from the Swiss National Science Foundation (10002235). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.